Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Gyre Therapeutics |
554.75 Mn |
540.62 Mn |
8.38 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
-404.41% |
| Dec 31, 2025 |
-147.73% |
| Sep 30, 2025 |
716.74% |
| Jun 30, 2025 |
-83.62% |
| Mar 31, 2025 |
2,825.25% |
| Dec 31, 2024 |
-108.81% |
| Sep 30, 2024 |
-68.14% |
| Jun 30, 2024 |
-53.16% |
| Mar 31, 2024 |
107.46% |
| Dec 31, 2023 |
-2,640.39% |
| Sep 30, 2023 |
114.57% |
| Jun 30, 2023 |
-17.42% |
| Mar 31, 2023 |
107.50% |
| Dec 31, 2022 |
-512.41% |
| Sep 30, 2022 |
-109.46% |
| Jun 30, 2022 |
455.20% |
| Mar 31, 2022 |
28.43% |
| Dec 31, 2021 |
19.53% |
| Sep 30, 2021 |
-26.65% |
| Jun 30, 2021 |
11.19% |
